Open AccessEconomic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy
Author(s) -
François Laliberté,
Veronica Ashton,
Akshay Kharat,
Dominique Lejeune,
Kenneth Todd Moore,
Young Yun Jung,
Patrick Lefèbvre,
Jeffrey S. Berger
Publication year - 2021
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2021-0150
Subject(s) - rivaroxaban , polypharmacy , medicine , warfarin , atrial fibrillation , obesity , emergency medicine
Aim: Evaluate healthcare resource utilization (HRU) and costs associated with rivaroxaban and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and polypharmacy. Materials & methods: IQVIA PharMetrics ® Plus (January 2010–September 2019) data were used to identify NVAF patients with obesity (BMI ≥30 kg/m 2 ) and polypharmacy (≥5 medications) initiated on rivaroxaban or warfarin. Weighted rate ratios and cost differences were evaluated post-treatment initiation. Results: Rivaroxaban was associated with significantly lower rates of HRU, including hospitalization (rate ratio [95% CI]: 0.83 [0.77, 0.92]). Medical costs were reduced in rivaroxaban users (difference [95% CI]: -US$6868 [-US$10,628, -US$2954]), resulting in significantly lower total healthcare costs compared with warfarin users (difference [95% CI]: -US$4433 [-US$8136, -US$582]). Conclusion: Rivaroxaban was associated with lower HRU and costs compared with warfarin among NVAF patients with obesity and polypharmacy in commercially insured US patients.